Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive overall disease.

Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.

A recent research letter reveals a strong connection between the consumption of ultra-processed foods and psoriasis flare-ups ...

Strategic appointments support further growth and position Company for future successWESTLAKE VILLAGE, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) ...

An itch can drive you absolutely crazy, but there are times when scratching only makes it worse—throwing your body's ...

After you try this wake up gel on your eyes and see the difference, you're gonna wonder if you were a witch the whole time.

Thinning edges are common due to styling practices, health conditions, and more. Read on to see the five tips dermatologists ...